Philips promotes new x-ray dose study at EuroPCR

Royal Philips Electronics, parent company of Philips Healthcare, in a joint study with the Radboud University Nijmegen Medical Centre in the Netherlands and Main-Taunus Cardiac Center in Germany, has announced that a 50% reduction in x-ray dose may be achieved in image-guided cardiac interventions using the AlluraClarity angiography system with ClarityIQ technology.

The study results are due to presented during the annual congress of the European Association of Percutaneous Cardiovascular Interventions (EuroPCR), being held 21-24 May in Paris.

The study was conducted between September and November 2012. It involved 39 patients with a body mass index range of 20 to 37. During the study, two coronary angiography scans of the same patient were compared: conventional interventional x-ray and Philips' AlluraClarity system with ClarityIQ. Six independent interventional cardiologists evaluated the image quality and concluded AlluraClarity provided equivalent image quality at 50% less x-ray dose (less than 1 mSv) compared with conventional interventional x-ray.

Additional studies using AlluraClarity in the field of neuroradiology and electrophysiology are ongoing, with results expected later this year, Philips said.

Philips is also highlighting at EuroPCR its EchoNavigator live image guidance tool and Allura Centron, an addition to the Allura line of interventional systems. Allura Centron is a high-performance multipurpose interventional x-ray system for routine procedures.

Philips AlluraClarity is currently not available for sale in the U.S.; the 510(k) clearance is pending.

Page 1 of 71
Next Page